Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

MOA lysozyme nasal spray preparation and preparation method thereof

A technology of lysozyme and nasal spray, applied in biochemical equipment and methods, local antibacterial agents, enzymes, etc., can solve the problems of poor use feeling and poor anti-inflammatory effect, and achieve the effect of improving nasal discharge symptoms and preventing inflammation

Pending Publication Date: 2020-12-11
浙江丽能生物医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chronic rhinitis can be divided into chronic simple rhinitis and chronic hypertrophic rhinitis, and the existing nasal sprays have poor anti-inflammatory effects and poor user experience

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The method for preparing MOA lysozyme nasal spray preparation comprises the steps:

[0029] Step 1: Mix 1 part of chlorhexidine acetate, 5 parts of MOA lysozyme, 1 part of glycerin, 1 part of witch hazel extract, 1 part of honeysuckle extract, 0.1 part of azelastine hydrochloride, and 1 part of recombinant human epidermal growth factor , 1 part of water-soluble chitosan, 1 part of glycerin, 1 part of sodium lactate, and 1 part of borneol were subjected to separation and sterilization treatment, ultrasonically extracted twice at 75 ° C, and put into raw material storage tanks respectively to obtain mixed raw materials.

[0030] Step 2: adding pure water to the mixed raw materials, dispersing and homogenizing, and using an ultrafiltration membrane with a molecular weight cut-off of 10000D to perform ultrafiltration separation to obtain a filtrate;

[0031] Step 3: sending the filtrate into an ion-exchange resin chromatography column for chromatography, and eluting with et...

Embodiment 2

[0035] Step 1: Mix 3 parts of chlorhexidine acetate, 20 parts of MOA lysozyme, 5 parts of glycerin, 5 parts of witch hazel extract, 5 parts of honeysuckle extract, 2 parts of azelastine hydrochloride, and 10 parts of recombinant human epidermal growth factor , 10 parts of water-soluble chitosan, 5 parts of glycerin, 4 parts of sodium lactate, and 4 parts of borneol were subjected to separation and sterilization treatment, ultrasonically extracted 3 times at 80° C., and put into raw material storage tanks respectively to obtain mixed raw materials.

[0036] Step 2: adding pure water to the mixed raw materials, dispersing and homogenizing, and using an ultrafiltration membrane with a molecular weight cut-off of 10000D to perform ultrafiltration separation to obtain a filtrate;

[0037] Step 3: sending the filtrate into an ion-exchange resin chromatography column for chromatography, and eluting with ethanol after chromatography, collecting and obtaining qualified eluted liquid;

...

Embodiment 3

[0041] Step 1: 2 parts of chlorhexidine acetate, 12 parts of MOA lysozyme, 3 parts of glycerin, 3 parts of witch hazel extract, 3 parts of honeysuckle extract, 1 part of azelastine hydrochloride, 5 parts of recombinant human epidermal growth factor, 5 parts of water-soluble chitosan, 3 parts of glycerin, 2 parts of sodium lactate, and 2 parts of borneol were separated and sterilized, ultrasonically extracted 3 times at 77°C, and put into raw material storage tanks respectively to obtain mixed raw materials.

[0042] Step 2: adding pure water to the mixed raw materials, dispersing and homogenizing, and using an ultrafiltration membrane with a molecular weight cut-off of 10000D to perform ultrafiltration separation to obtain a filtrate;

[0043] Step 3: sending the filtrate into an ion-exchange resin chromatography column for chromatography, and eluting with ethanol after chromatography, collecting and obtaining qualified eluted liquid;

[0044] Step 4: Filter the eluted solutio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of nasal sprays, and particularly relates to an MOA lysozyme nasal spray preparation and a preparation method thereof. The preparation is prepared from, byweight, 1-3 parts of chlorhexidine acetate, 5-20 parts of MOA lysozyme, 1-5 parts of glycerin, 1-5 parts of witch hazel extract, 1-5 parts of honeysuckle extract, 0.1-2 parts of azoospirin hydrochloride, 1-10 parts of recombinant human epidermal growth factor, 1-10 parts of water-soluble chitosan, 1-5 parts of glycerol, 1-4 parts of sodium lactate and 1-4 parts of borneol. By adding superoxide dismutase, the nasal spray preparation can effectively improve the symptoms of nasal obstruction and nasal mucus, and make blood vessels contract to relieve blood stasis and ventilate the nose, and hassignificant effects on inhibiting staphylococcus aureus, escherichia coli, candida albicans, bacterial infection and allergic symptoms. The recombinant human epidermal growth factor (rhEGF) mainly plays a role in promoting regeneration of nasal mucosa and repairing nasal mucosa, sodium lactate keeps the nasal cavity moist, and borneol mainly plays a role in restoring consciousness and opening orifices to enhance the use experience.

Description

technical field [0001] The invention relates to the technical field of nasal sprays, in particular to a MOA lysozyme nasal spray preparation and a preparation method thereof. Background technique [0002] Rhinitis is an inflammatory disease of the nasal cavity, which is an inflammation of the nasal mucosa caused by viruses, bacteria, allergens, various physical and chemical factors, and certain systemic diseases. The main pathological changes of rhinitis are congestion, swelling, exudation, hyperplasia, atrophy or necrosis of nasal mucosa. [0003] Rhinitis is divided into acute rhinitis and chronic rhinitis. Acute rhinitis is an acute inflammatory disease of nasal mucosa caused by viral infection, commonly known as cold and cold. Symptoms include nasal congestion, runny nose, fever, etc., and the course of the disease usually lasts for 7 to 10 days. More than 200 viruses are associated with acute rhinitis. It can occur in all seasons, and it is more common in winter. Wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/47A61K9/12A61K47/36A61P11/02A61P31/02A61K31/045A61K31/047A61K31/155A61K31/19A61K31/55A61K36/355A61K38/18
CPCA61K38/47C12Y302/01017A61K31/155A61K36/185A61K36/355A61K38/1808A61K31/047A61K31/045A61K31/19A61K31/55A61K9/0043A61K47/36A61P11/02A61P31/02A61K2300/00Y02A50/30
Inventor 方寅钢
Owner 浙江丽能生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com